Abstract
With the increasing use of artificial kidneys, numerous reports have appeared describing the pharmacokinetics of administered drugs in dialysis patients. Unfortunately, different investigators use different measures of dialysis clearance in reporting their results. Few studies have appeared in which actual measurements have been made in blood and dialysate as well as in plasma to experimentally show the variability of individual measurements and to demonstrate the inaccuracy of certain clearance measurements. We do so here, using the drug ethambutol. The effect of the artificial kidney on the removal of ethambutol was investigated in four uremic patients undergoing chronic hemodialysis. Ethambutol was administered by i.v. infusion over 30 min. Hemodialysis started at the end of drug infusion. Blood, plasma, and dialysate samples were collected periodically over 3 hr and analyzed for ethambutol content. Dialysis clearance was calculated by arterialvenous difference and by simultaneous dialysate measurement. The extraction efficiency of the hollow fiber dialyzers ranged from 36.2% to 43.8% in terms of blood and from 38.0% to 45.4% in terms of plasma. The mean clearance values due to dialysis were 108.08 and 88.1 ml/min measured with plasma and blood as body fluids of reference, respectively. Dialysis clearance calculated by dialysate measurement had a mean of 85.9 ml/min expressed as plasma and 74.7 ml/min expressed as blood. This study demonstrates that dialysis clearance when calculated using A-V difference and plasma flow is generally underestimated, particularly for a drug which extensively partitions into red blood cells. Ethambutol had a partition coefficient (blood/plasma) of greater than 1 in all four patients. The β phase exhibited a mean half-life of approximately 2 hr on dialysis in comparison to off dialysis half-lives of 7 hror longer in renal failure. Although ethambutol exhibits a markedly reduced half-life of the drug during hemodialysis, its recovery in the dialysis fluid during a 3-hr dialysis period constitutes only a small fraction of the dose administered.
Similar content being viewed by others
References
T. P. Gibson and H. A. Nelson. Drug kinetics and artificial kidneys.Clin. Pharmacokin. 2:402–426 (1977).
O. Bass, K. D. Nolph, and J. E. Maher. Dialysance and clearance measurements during clinical dialysis—A plea for standardization.J. Lab. Clin. Med. 86:378–385 (1975).
F. A. Gotch. Hemodialysis: Technical and kinetic considerations. In B. M. Brenner and F. C. Rector (eds.),The Kidney, Saunders, Philadelphia, 1976, pp. 1672–1704.
T. P. Gibson, E. Matusik, L. D. Nelson, and W. A. Briggs. Artificial kidneys and clearance calculations.Clin. Pharmacol. Ther. 20:720–726 (1976).
T. P. Gibson. Dialyzability of common therapeutic agents.Dialysis Transplant.8:24–40 (1979).
C. S. Lee and L. Z. Benet. Ethambutol Hydrochloride. In K. Florey (ed.),Analytical Profiles of Drug Substances, Vol. 7, Academic Press, New York, 1978, pp. 231–249.
C. S. Lee and L. Z. Benet. Gas-liquid chromatographic determination of ethambutol in plasma and urine of human and monkey.J. Chromatogr. 128:188–192 (1976).
C. S. Lee and L. Z. Benet. Micro and macro GLC determination of ethambutol in biological fluids.J. Pharm. Sci. 67:470–473 (1978).
C. S. Lee, J. G. Gambertoglio, D. C. Brater, and L. Z. Benet. Kinetics of oral ethambutol in the normal subject.Clin. Pharmacol. Ther. 22:615–621 (1977).
C. S. Lee, D. C. Brater, J. G. Gambertoglio, and L. Z. Benet. Disposition kinetics of ethambutol. Presented before the Basic Pharmaceutics Section at the Annual Meeting of APhA Academy of Pharmaceutical Science, Montreal, Canada, May 1978.
G. L. Bailey and J. P. Vona. Pharmacodynamics in renal failure. In G. L. Bailey (ed.),Hemodialysis Principles and Practice, Academic Press, New York, 1972, pp. 117–186.
Th. Dume, Cl. Wagner, and E. Wetzels. Pharmacokinetics of ethambutol in healthy subjects and in patients with terminal renal failure.Deutsch. Med. Wschr. 96:1430–1434 (1971).
T. G. Christopher, A. Blair, A. Forrey, and R. E. Cutler. Kinetics of ethambutol elimination in renal disease.Proc. Dialysis Transplant Forum 3:96–100 (1973).
V. A. Place, E. A. Peets, D. A. Buyske, and R. R. Little. Metabolic and special studies of ethambutol in normal volunteers and tuberculosis patients.Ann. N. Y. Acad. Sci. 135:775–795 (1966).
L. Anex, G. Favez, and C. Willa. Comparison entre les clearances rénales à l'inuline et au para-amino-hippurate et les concentrations sanguines de l'ethambutol.Schweiz. Med. Wschr. 102:126–128 (1972).
T. N. Tozer, L. D. Witt, L. Gee, T. G. Tong, and J. Gambertoglio. Evaluation of hemodialysis for ethchlorvynol (Placidyl) overdose.Am. J. Hosp. Pharm. 31:986–989 (1975).
Author information
Authors and Affiliations
Additional information
This work was supported in part by NIH Grant GM 26551.
Rights and permissions
About this article
Cite this article
Lee, C.S., Marbury, T.C. & Benet, L.Z. Clearance calculations in hemodialysis: Application to blood, plasma, and dialysate measurements for ethambutol. Journal of Pharmacokinetics and Biopharmaceutics 8, 69–81 (1980). https://doi.org/10.1007/BF01059449
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059449